Articles tagged with Drug Studies
A study co-led by McMaster University found that fluvoxamine can save the lives of COVID-19 patients and reduce hospital admissions by up to 30%. The treatment was effective in preventing COVID-19 from becoming a life-threatening illness when administered early.
Researchers at Shanghai Institute of Materia Medica have isolated and characterized seven novel dimeric sesquiterpenoids with potent antimalarial activities. The most potent compound, Shizukaol A, exhibits an EC50 value 1000-fold more active than artemisinin.
The largest trial to date shows that fluvoxamine treatment for high-risk outpatients with early-diagnosed COVID-19 reduces the need for prolonged observation or hospitalization. The study found an absolute reduction in risk of prolonged hospitalization and a relative risk reduction of 32% compared to the control group.
A recent Johns Hopkins Medicine-led study suggests that statin use is not beneficial for reducing COVID-19 mortality or severity. Instead, patients taking statins had an increased risk of developing a more severe form of the disease. The researchers found no significant impact on mortality rates.
A Singapore clinical trial has introduced a new way to treat advanced hepatocellular carcinoma by combining nivolumab, an immunotherapy drug, with yttrium-90 resin microspheres radioembolisation. The study shows promising results in treating intermediate and advanced HCC, with an overall response rate of 30.6%.
Researchers have discovered a more effective treatment for children with Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C), a rare COVID-19 reaction. The new therapy, infliximab, reduces fever duration, hospitalizations, and anemia compared to standard IVIG treatment.
A study by University of Toronto researchers found that using prescription stimulant medications increased the risk of cardiovascular events by 40% in older adults within the first 30 days. The risk was highest during initial use, but decreased over time as patients stopped taking the medication.
A new study reveals that rural Americans face significant challenges in accessing COVID-19 treatment trials, with many living more than an hour away from the nearest trial site. Native Americans and Alaska Natives are particularly affected, with over 50% living more than 60 minutes from a trial site.
Research reviews show that back pain in space is often sciatica, a form of back pain radiating down the legs. Astronauts experience changes in spine curvature due to microgravity, leading to acute and chronic pain upon return to Earth.
A new study has shown that a commonly prescribed antidepressant for agitation in people with dementia is no more effective than a placebo and may even increase mortality. The research found no improvement in agitation symptoms among those taking mirtazapine, a drug previously thought to be beneficial.
Researchers found that adding interferon to bone marrow transplant significantly reduced leukemia relapse among high-risk patients, improving outcomes. The study suggests a potential new strategy for treating advanced acute myeloid leukemia, with further research needed to confirm the findings.
About 42% of U.S. adults are considered clinically obese due to increased risk of health conditions such as diabetes and heart disease. New weight-loss drugs like Wegovy (semaglutide) show promise in safely aiding weight loss, but long-term side effects and sustainability remain concerns.
Researchers at University of Pittsburgh and Prairie View A&M University developed an algorithm to repurpose cancer drugs for pulmonary hypertension, a devastating lung disease. Two compounds improved human cells and rodent markers, supporting broader drug-repurposing platform use.
A meta-analysis of randomized controlled trials found lactoferrin to have promising efficacy in reducing the risk of respiratory tract infections, including COVID-19. Lactoferrin may also play a beneficial role in managing symptoms and recovery for patients suffering from RTIs.
Researchers have identified several commonly prescribed medications that can affect the flu virus's interaction with host cells. Some of these medications amplify the virus's effect, while others dampen it, depending on their target in the cells. Further research is needed to understand the consequences of these interactions for patients.
Researchers discovered a mechanism that could prove useful in treating heart failure with preserved ejection fraction (HFpEF), a common and hard-to-treat condition. The new approach reduces exposure to increased cardiac stiffness, which is associated with lower-filling pressures inside the heart chambers.
Two new studies examine rising cancer drug spending in the US, finding that many patients receive treatments with no documented overall survival benefit. The studies suggest that the combination of regulatory, pricing, and reimbursement policies contributes to wasteful healthcare spending.
A phase II clinical trial has shown that the DNA alkylation drug DM-CHOC-PEN improved survival in adolescent and young adult patients with central nervous system cancers. The treatment was well-tolerated, with no severe toxicities observed, and showed potential for combination with other treatments.
Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.
Researchers found a chemical inhibitor of PDE9 stimulates cells to burn more fat in mice, reducing obesity and fatty liver. The study's findings suggest the experimental drug may be effective in treating severe obesity and improving heart function.
A new study suggests that increased access to naloxone has not changed people's perception of the risks associated with heroin use. Researchers found that individuals who used heroin and those living in areas with easy or restricted access to naloxone both perceived heroin as a high-risk substance.
A simulated screening process for a pancreatic cancer clinical trial showed that Black patients were significantly more likely than white patients to be excluded from trials. The study found that nutrition and infectious disease criteria disproportionately excluded Black patients, while a history of prior cancer treatment excluded more...
The ARAMIS phase III clinical trial found that darolutamide improved metastasis-free survival and overall survival in Black/African American patients. Darolutamide-treated patients had a higher three-year overall survival rate and longer time to disease progression compared to placebo-treated patients.
A pre-clinical study by University of Illinois Chicago researchers shows that a drug targeting specific immune pathways can prevent lung damage and death in mice infected with the SARS-CoV-2 virus. The study suggests targeted treatments may be more suitable for COVID-19 patients than broad immune suppressants.
A study analyzing 60 US emergency departments found medication harms were a common cause of visits in 2017-2019, with variation in products and patient age. The data highlighted the need for improved safety measures and monitoring systems to mitigate such incidents.
A team of scientists developed a new method to study the effects of reactive electrophiles in the body. By targeting specific proteins with electrophilic compounds, they discovered novel mediators involved in immune-cell apoptosis triggered by Tecfidera, a multiple sclerosis treatment.
A recent study found that pediatric patients with Multisystem Inflammatory Syndrome (MIS-C) who received initial IVIG plus Infliximab had improved cardiac outcomes, reduced need for additional therapies, and faster resolution of inflammation. The updated care pathway recommends this intensified therapy for all MIS-C patients.
A new study by UCL researchers has found that staying on long-term antidepressants reduces the risk of relapse by 39% compared to those who stop taking them. The study involved 478 primary care patients and found that 56% experienced a relapse within a year if they discontinued their medication, while only 26% did so after a full year.
Scientists at Temple University will explore the therapeutic potential of KLS-13019, a CBD analog that shows promise as an opioid alternative. The Phase 2 SBIR grant aims to test the compound's effects on rat models of neuropathic pain, shedding light on its safety and efficacy.
A clinical trial conducted by TTUHSC researchers found that corneal epithelial stem cell-derived eye drops significantly improved symptoms of severe dry eye disease, with patients experiencing a 23% improvement in SPEED questionnaire scores and a 17.1% improvement in OSDI scores. No adverse reactions were reported during the 12-week tr...
A new study at Ohio State University's Comprehensive Cancer Center is using rapid autopsies to gather biological samples after death to better understand how cancer cells overcome different treatments. This approach has already led to novel findings about drug resistance mechanisms, including the recent approval of a targeted therapy f...
Researchers have identified a way to restore the effectiveness of drugs in clinical trials for treating AML by using human alpha(1)-acid glycoprotein (AGP) as a 'decoy' to bind and inhibit FLT3-mutated leukemia cells. The approach has potential for improving patient outcomes, particularly for patients with FLT3-mutated AML.
New targeted therapies are being developed to target genetic alterations in cancer cells, such as the ARID1A mutation found in 10-50% of solid tumours. Early clinical trials suggest that these agents may be effective in treating multiple cancers, including breast, ovarian, and gastric cancer.
A recent study published in JNCCN found that four out of five cancer therapies tested in Phase III trials did not achieve clinically-meaningful benefits in prolonging survival. The researchers analyzed 362 industry-sponsored trials and found that 87% were either false-positive or true-negative for meeting overall survival goals.
Patients with certain gene mutations are at high risk of fatal chemotherapy toxicity, with a 25-times increased risk detected in those with uncommon DPYD variants. The study suggests that adding pre-treatment screening may help prevent avoidable deaths without interrupting standard care.
The FIRSTMAPPP trial found that sunitinib significantly prolongs progression-free survival in patients with malignant pheochromocytoma and paraganglioma. The study demonstrated the efficacy of sunitinib as a treatment option for this rare cancer, which is commonly treated with old and toxic agents.
The MONALEESA-2 trial found that adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The combination of endocrine therapy and the CDK 4/6 inhibitor ribociclib also extends progression-free survival.
A Phase III trial showed a significant overall survival benefit of 63.9 months with ribociclib, compared to 51.4 months with hormone therapy alone. The estimated six-year survival rate was 44.2% with ribociclib, compared to 32% for placebo.
Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.
A new trial run by UCL researchers shows promise in slowing the regrowth of tumors among some bowel cancer patients. The drug adavosertib was found to delay tumour growth by about two months on average and had relatively few side effects, particularly in left-sided/rectal tumours.
A clinical trial found that over half of patients with non-small cell lung cancer (NSCLC) with a HER2 gene mutation had their tumors stop growing or shrink after treatment with trastuzumab deruxtecan. The drug showed durable responses in 54.9% of patients, with median survival period of 17.8 months.
Researchers from University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine found that combining long-term injectable medications with psychosocial intervention improves adherence and symptoms in patients with bipolar disorder. The study enrolled 30 people with bipolar disorder who had adherenc...
Using surrogate endpoints to measure new drug efficacy can reduce trial costs and complexity but also makes decisions more challenging for patients and clinicians. Experts call for more selective use of surrogate endpoints in chronic diseases with patient-relevant outcomes.
A two-dose Ebola vaccine regimen has been found to be safe, well-tolerated, and produce a strong immune response in people over 1 year old. The study also supports the use of this regimen for Ebola virus disease prevention in children and adults.
Researchers have identified nine FDA-approved drugs that can effectively suppress SARS-CoV-2 replication in human cells. These compounds have been shown to be safe in humans and could potentially provide an alternative treatment for COVID-19 patients.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
Researchers found that certain species of gut bacteria accumulate human drugs, altering their types, activity, and metabolism. This can change the effectiveness of the drug both directly and indirectly, affecting side effects.
The GPGD database contains records for 903 herb species, including DNA barcodes, organelle genomes, and whole genomes. It provides essential resources for species identification, biosynthetic pathway decomposition, and molecular-assisted breeding analysis.
The first-in-human clinical trial for a vaccine to treat opioid use disorders has enrolled its first patients. The vaccine, developed by researchers at the University of Minnesota Medical School, aims to selectively prevent the euphoric and toxic effects of oxycodone.
A modified chemotherapy regimen for Burkitt lymphoma has been developed, combining CODOX-M and IVAC with rituximab, to reduce toxicity and improve survival rates. The study found a higher overall survival rate and lower frequency of severe side effects compared to standard regimens.
Researchers from Florida Atlantic University's Schmidt College of Medicine review recent randomized trials, concluding that hydroxychloroquine poses significant harm in treating COVID-19. The study suggests a halt on prescribing the medication, recommending vaccination and masking instead as effective public health strategies.
The MASTER DAPT trial found that one month of dual antiplatelet therapy preserves ischemic benefits and reduces bleeding risk in high bleeding risk patients. Abbreviated DAPT was noninferior to standard DAPT in terms of net adverse clinical events, but superior in reducing major or clinically relevant nonmajor bleeding.
Researchers reviewed 79 studies on neurocognitive impairments and brain abnormalities associated with nonfatal opioid overdoses in humans. The findings suggest a link between overdose, cognitive impairment, and brain changes, which could influence attention span, memory, and executive function.
The FIGARO-DKD trial found that finerenone improved cardiovascular outcomes in patients with mild-to-moderate kidney disease and type 2 diabetes. Finerenone reduced the risk of cardiovascular morbidity and mortality by 13%, largely driven by a 29% reduction in hospitalization for heart failure.
A combination therapy of aspirin, statins, and at least two blood pressure medications cuts the risk of fatal cardiovascular disease by over half. The treatment strategy, known as a polypill, is consistent in benefits across different blood pressure levels, cholesterol levels, and diabetes status.
A new strategy using a pill containing four medicines has been shown to be more effective in getting blood pressure under control compared to traditional monotherapy, with 80% of participants achieving blood pressure control within 12 weeks.
A large clinical trial has identified empagliflozin as a treatment option for heart failure with preserved ejection fraction, reducing risk of hospitalization or death by 21 percent. The drug also showed fewer symptoms and mild side effects.
A clinical trial has shown that a triple combination therapy consisting of elexacaftor, tezacaftor, and ivacaftor is safe and effective in cystic fibrosis patients with rare genetic defects. The treatment improves CFTR function, lung function, and quality of life in these patients.
A Phase 2 trial found that combining cisplatin, gemcitabine, and berzosertib did not prolong progression-free survival in patients with urothelial cancer. The study suggests that berzosertib may have a negative impact on bone marrow, leading to reduced white blood cells and platelets.
A new TB prevention regimen for HIV-positive individuals has shown promising results, with 90.4% completing the three-month course compared to 50.5% of those on a six-month daily treatment. The study suggests that this shorter approach is as safe and effective as the standard treatment.